DOSSIER · 13F Holders · Q2 2026Healthcare · Biological Products, (No Diagnostic Substances)
RXRX
RECURSION PHARMACEUTICALS IN
372 institutions still hold RECURSION PHARMACEUTICALS IN as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
CUSIP 75629V104·Biological Products, (No Diagnostic Substances)·372 13F holders·last filed Jun 30, 2026
AI Holders Summary · Q2 2026
372 institutions reported RXRX in Q2 2026. BlackRock, Inc. leads at 15.9% of the visible book.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.
Page 1 of 19
352 more holders available. Log in →